TY - JOUR
T1 - A comparison of cyclophosphamide, adriamycin, 5‐fluorouracil (CAF) and cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A southeastern cancer study group project
AU - Smalley, R. V.
AU - Carpenter, J.
AU - Bartolucci, A.
AU - Vogel, C.
AU - Krauss, S.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1977/8
Y1 - 1977/8
N2 - In an ongoing prospective randomized study, 113 evaluable patients have received either a three-drug combination that included cyclophosphamide, adriamycin and 5-fluorouracil (CAF) or a five-drug combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features.
AB - In an ongoing prospective randomized study, 113 evaluable patients have received either a three-drug combination that included cyclophosphamide, adriamycin and 5-fluorouracil (CAF) or a five-drug combination including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) given intermittently 1 week out of 4. Responses (64%), median duration of response (32 weeks), and median duration of disease control (32 weeks) achieved with CAF were superior to those achieved with CMFVP (37%, 22 weeks, 17 weeks, respectively). Morbidity secondary to CAF was significant, with nausea and vomiting, malaise, total alopecia, and granulocytopenia being the main features.
UR - http://www.scopus.com/inward/record.url?scp=0017667562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017667562&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M
DO - 10.1002/1097-0142(197708)40:2<625::AID-CNCR2820400206>3.0.CO;2-M
M3 - Article
C2 - 329975
AN - SCOPUS:0017667562
VL - 40
SP - 625
EP - 632
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 2
ER -